NCT04072432已完成1 期
A Phase 1b Dose-escalating Study With RBT-3 in Healthy Volunteers and Volunteers With Chronic Kidney Disease Stage 3/4
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 18
- 试验地点
- 1
- 主要终点
- Effect of RBT-3 on Plasma Ferritin Levels
研究概览
简要总结
This is a Phase 1b, single center, dose-escalating study evaluating the safety, tolerability, and pharmacodynamic effect of RBT-3 in healthy volunteers and in subjects with stage 3-4 chronic kidney disease.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Sequential
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Male and female subjects age 18 to 80 years (inclusive, at time of ICF).
- •Body weight <125 kg.
- •Able and willing to comply with all study procedures.
- •Female subjects must be either post-menopausal for at least 1 year or surgically sterile (tubal ligation, hysterectomy or bilateral oophorectomy) for at least 3 months, or if of childbearing potential, have a negative pregnancy test and agree to use dual methods of contraception, or abstain from sexual activity from Screening until 8 days after study drug administration.
- •Male subjects with female partners of childbearing potential must agree to use a highly effective method of contraception from screening until 8 days after study drug administration. All fertile men with female partners of childbearing potential should be instructed to contact the Investigator immediately if they suspect their partner might be pregnant (e.g., missed or late menstrual period) at any time during study participation.
- •CKD as determined by estimated glomerular filtration rate (eGFR) between 15-59 ml/min as estimated using the CKD-EPI equation (CKD class 3-4).
排除标准
- •History of malignancy except carcinoma in situ in the cervix, early stage prostate cancer or non-melanoma skin cancers.
- •Use of investigational drugs or participation in another clinical trial within 30 days or 5 half-lives prior to screening, whichever is longer.
- •Serum ferritin > 500 ng/ml or who have received IV iron within 28 days of screening.
- •Women who are pregnant, breastfeeding, or planning to become pregnant while participating in the study.
- •Any significant acute or chronic diseases, excluding CKD (eGFR ≥15 ml/min).
- •Regular use of drugs of abuse and/or positive findings on urinary drug screening.
- •Current tobacco use and/or positive findings on urinary cotinine screening.
- •Subjects who are severely physically or mentally incapacitated and who, in the opinion of investigator, are unable to perform the subjects' tasks associated with the protocol.
- •Presence of any condition which, in the opinion of the investigator, places the subject at undue risk or potentially jeopardizes the quality of the data to be generated.
- •Known hypersensitivity or previous anaphylaxis to FeS.
研究组 & 干预措施
360 mg
Experimental
干预措施: RBT-3 (Drug)
120 mg
Experimental
干预措施: RBT-3 (Drug)
240 mg
Experimental
干预措施: RBT-3 (Drug)
结局指标
主要结局
Effect of RBT-3 on Plasma Ferritin Levels
时间窗: 24 hours post-infusion
Effect of RBT-3 on Plasma HO-1 Levels
时间窗: 24 hours post-infusion
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Study of RBT-1 in Healthy Volunteers and Subjects With Stage 3/4 Chronic Kidney DiseaseChronic Kidney DiseaseNCT03893799Renibus Therapeutics, Inc.54
已完成
1 期
A Study of RBT-9 in Healthy Volunteers and Volunteers With Stage 3/4 Chronic Kidney DiseaseHealthy VolunteersChronic Kidney DiseaseNCT04072861Renibus Therapeutics, Inc.42
撤回
1 期
RBT-1 Phase 1b Clinical Trial in Healthy Volunteers and Subjects With CKDAcute Kidney InjuryNCT03630029Renibus Therapeutics, Inc.
招募中
1 期
Study of TBI-2001(Autologous CD19 Specific Chimeric Antigen Receptor (CAR) Gene-transduced T Lymphocytes) for Relapsed or Refractory CD19+ B-cell Lymphoma, CLL/SLLRelapsed or Refractory CD19+ B-cell LymphomaRelapsed or Refractory Chronic Lymphocytic LeukemiaRelapsed or Refractory Small Lymphocytic LymphomaNCT05963217University Health Network, Toronto19
终止
2 期
A Study to Evaluate the Effect of RBT-9 on Progression of COVID-19 in High-Risk Individuals (The PREVENT Study)COVID-19NCT04364763Renibus Therapeutics, Inc.42